0.75
price down icon1.72%   -0.0131
 
loading
전일 마감가:
$0.7631
열려 있는:
$0.75
하루 거래량:
462.01K
Relative Volume:
0.43
시가총액:
$15.69M
수익:
$2.05M
순이익/손실:
$-23.15M
주가수익비율:
-0.1131
EPS:
-6.6319
순현금흐름:
$-16.93M
1주 성능:
+0.27%
1개월 성능:
-2.60%
6개월 성능:
-69.39%
1년 성능:
-62.69%
1일 변동 폭
Value
$0.7202
$0.75
1주일 범위
Value
$0.68
$0.81
52주 변동 폭
Value
$0.6358
$6.8908

iBio Inc Stock (IBIO) Company Profile

Name
명칭
iBio Inc
Name
전화
302-355-0650
Name
주소
600 Madison Avenue, Suite 1601, New York, NY
Name
직원
54
Name
트위터
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
IBIO's Discussions on Twitter

IBIO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
IBIO
iBio Inc
0.75 15.69M 2.05M -23.15M -16.93M -6.6319
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.34 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.02 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
555.31 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.33 28.51B 3.81B -644.79M -669.77M -6.24

iBio Inc Stock (IBIO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-05-28 개시 Chardan Capital Markets Buy
2021-11-29 개시 JMP Securities Mkt Outperform
2021-01-22 개시 Cantor Fitzgerald Overweight
2020-06-26 개시 Alliance Global Partners Buy

iBio Inc 주식(IBIO)의 최신 뉴스

pulisher
Jun 18, 2025

iBio Extends Promissory Note Maturity to 2026 - TipRanks

Jun 18, 2025
pulisher
Jun 17, 2025

Ibio nominates IBIO-610 as obesity development candidate - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 16, 2025

iBio initiates primate study for obesity antibody candidate IBIO-610 By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 16, 2025

iBio (IBIO) Begins Preclinical Study of New Antibody Candidate | - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

iBio initiates primate study for obesity antibody candidate IBIO-610 - Investing.com

Jun 16, 2025
pulisher
Jun 16, 2025

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment | IBIO Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

iBio initiates non-human primate study of IBIO-610 - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Breakthrough Obesity Drug Shows 77% Fat Reduction When Combined With GLP-1 Treatments - Stock Titan

Jun 16, 2025
pulisher
Jun 13, 2025

iBio (IBIO) Plans to Offer 11.25 Million Shares of Common Stock - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Sector Update: Health Care - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

IBio Files Prospectus for Resale of About 11.3 Million Shares - marketscreener.com

Jun 13, 2025
pulisher
Jun 10, 2025

Plant-Based Vaccines Market Future Business Opportunities 2025-2032 | Medicago, Inc., IBIO, Icon Genetics GmbH - newstrail.com

Jun 10, 2025
pulisher
May 29, 2025

iBio: University of Limerick programme to ‘shape the next generation’ of pharmaceutical manufacturing experts - University of Limerick

May 29, 2025
pulisher
May 23, 2025

Merck & Co., Inc. (MRK): A Bull Case Theory - MSN

May 23, 2025
pulisher
May 14, 2025

Plant-Based Vaccines Market Detailed In New Research Report - openPR.com

May 14, 2025
pulisher
May 11, 2025

Insiders Who Purchased US$655.0k Of iBio Stock May Not Have Expected 23% Tumble - simplywall.st

May 11, 2025
pulisher
May 11, 2025

Insider Buyers At iBio Likely Disappointed With 23% Slide - Yahoo Finance

May 11, 2025
pulisher
May 11, 2025

Chardan Capital Has Pessimistic View of iBio FY2025 Earnings - Defense World

May 11, 2025
pulisher
May 09, 2025

Chardan Capital Has Bearish Outlook for iBio FY2025 Earnings - Defense World

May 09, 2025
pulisher
May 07, 2025

Would I Consider iBio Inc (NASDAQ: IBIO) Stock Any Time In The Future? - Stocksregister

May 07, 2025
pulisher
May 06, 2025

Balance Sheet Dive: iBio Inc (IBIO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX

May 06, 2025
pulisher
May 06, 2025

iBio (IBIO) Rating Maintained at Buy by Chardan Capital | IBIO S - GuruFocus

May 06, 2025
pulisher
May 06, 2025

iBio’s (IBIO) Buy Rating Reaffirmed at Chardan Capital - Defense World

May 06, 2025
pulisher
May 06, 2025

iBio (NYSEMKT:IBIO) Shares Down 1.9% – Time to Sell? - Defense World

May 06, 2025
pulisher
May 05, 2025

iBio announces new preclinical data for Activin E antibody - TipRanks

May 05, 2025
pulisher
May 05, 2025

Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Pri - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Price Target | IBIO Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

iBio (IBIO) Reports Promising Results from Activin E Antibody Study | IBIO Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - The Manila Times

May 05, 2025
pulisher
May 05, 2025

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Revolutionary Obesity Treatment Achieves 77% Fat Reduction While Preserving Muscle Mass, Outperforms GLP-1s - Stock Titan

May 05, 2025
pulisher
May 04, 2025

iBio, Inc. Reports Strong Q3 2025 Progress - TipRanks

May 04, 2025
pulisher
May 04, 2025

iBio, Inc. (NYSE:IBIO) Shares Purchased by Geode Capital Management LLC - Defense World

May 04, 2025
pulisher
May 04, 2025

iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 20.9% in April - Defense World

May 04, 2025
pulisher
May 02, 2025

IBio Reports Fiscal Third Quarter 2025 Financial Results - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline - GuruFocus

May 02, 2025
pulisher
May 02, 2025

iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline | IBIO Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

iBio Reports Fiscal Third Quarter 2025 Financial Results | IBIO Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

iBio Reports Fiscal Third Quarter 2025 Financial Results - The Manila Times

May 02, 2025
pulisher
May 02, 2025

iBio, Inc. Reports Q3 2025 Financial Results and Corporate Progress Following Nasdaq Listing - Nasdaq

May 02, 2025
pulisher
May 02, 2025

iBio Reports Strong Pipeline Data and Nasdaq Uplisting as Q3 R&D Investment Doubles - Stock Titan

May 02, 2025
pulisher
Apr 30, 2025

Take off with iBio Inc (IBIO): Get ready for trading - Sete News

Apr 30, 2025
pulisher
Apr 30, 2025

iBio Raises $6.2 Million Through Warrant Inducement Transaction - The Manila Times

Apr 30, 2025
pulisher
Apr 29, 2025

Analyzing iBio Inc (IBIO) After Recent Trading Activity - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

iBio Raises $6.2 Million Through Warrant Inducement Transaction | IBIO Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Biotech Firm iBio Raises $6.2M in Fresh Capital: New Warrants Issued at $0.86 - Stock Titan

Apr 29, 2025
pulisher
Apr 29, 2025

What to expect from iBio Inc’s (IBIO) current quarter earnings? - uspostnews.com

Apr 29, 2025
pulisher
Apr 29, 2025

Teck Resources Ltd [TECK] Insider Activity: An Update for Investors - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

iBio (NYSE:IBIO) Trading Up 14.3% – Should You Buy? - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

An Overview of iBio Inc (NASDAQ: IBIO)’s Stock Performance and Outlook - Marketing Sentinel

Apr 28, 2025

iBio Inc (IBIO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

iBio Inc 주식 (IBIO) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Brenner Martin
See Remarks
Jan 10 '25
Buy
2.72
9,191
25,000
18,316
Banjak Marc
Chief Legal Officer
Jan 10 '25
Buy
2.72
9,191
25,000
11,066
Arkowitz David
Director
Jan 10 '25
Buy
2.72
18,382
49,999
18,382
Clark William D
Director
Jan 10 '25
Buy
2.72
1,838
4,999
1,838
Parada Antonio Bernardino Guim
Director
Jan 10 '25
Buy
2.72
183,823
499,999
183,823
Sender Gary
Director
Jan 10 '25
Buy
2.72
9,191
25,000
9,191
$21.00
price up icon 1.52%
$36.00
price down icon 0.06%
$21.32
price down icon 0.15%
$99.07
price down icon 1.72%
$108.80
price up icon 2.21%
biotechnology ONC
$244.86
price up icon 1.07%
자본화:     |  볼륨(24시간):